Diffuse large B-cell lymphoma: A retrospective study from a regional care center in South India.

Autor:	Babu SM; Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India., Garg S; Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India., Kanakasetty GB; Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India., Kuntegowdanahalli LC; Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India., Dasappa L; Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India., Rao SA; Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India.
Jazyk:	angličtina
Zdroj:	Indian journal of cancer [Indian J Cancer] 2018 Jan-Mar; Vol. 55 (1), pp. 66-69.
DOI:	10.4103/ijc.IJC_450_16
Abstrakt:	Introduction: Diffuse large B-cell lymphoma (DLBCL) is an aggressive lymphoma whose outcomes have significantly improved with rituximab in addition to anthracycline-based chemotherapy. Objective: This study aimed to study the epidemiology, treatment, and outcomes of patients with DLBCL. Materials and Methods: A total of 526 patients diagnosed with DLBCL between 2006 and 2015 were retrospectively analyzed. Results: The median age was 50 years with a male preponderance. Two hundred and twenty-three (42.39%) patients presented with B symptoms. A total of 53 (10.07%) patients presented with bulky disease and 202 (31.40%) with extranodal disease. The most common extranodal sites involved were the stomach (20.79%) and the bone marrow (10.89%). Bone marrow involvement was seen in only 22 (4.18%) cases. The distribution of patients presenting in low, low-intermediate, high-intermediate, and high-risk International Prognostic Index (IPI) were 148 (28.13%), 191 (36.31%), 124 (23.57%), and 63 (11.97%), respectively. The median survival of the entire cohort was 22 months. Survival of patients that compared the two groups with respect to the IPI - one having clubbed patients in low and low/intermediate risk and the other clubbing high/intermediate and high risk showed significantly improved survival in the lower risk groups - 24 versus 18 months (P = 0). The survival of those who received chemoimmunotherapy i.e R - CHOP was significantly better than those who received chemotherapy (CHOP) alone - 33 versus 21 months (P = 2.22e-16). Conclusions: DLBCL is one of the most common lymphomas seen in our daily practice. Outcomes are significantly inferior compared to western countries. Biological and patient-related factors such as nongerminal center B subtype, higher extranodal involvement, and poor tolerability to treatment could contribute to inferior outcomes. Competing Interests: There are no conflicts of interest
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu